Login / Signup

Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.

Rujittika PhD MungmunpuntipantipViroj Md Wiwanitkit
Published in: The Annals of pharmacotherapy (2022)
Keyphrases
  • coronavirus disease
  • sars cov
  • rheumatoid arthritis
  • early onset
  • high intensity
  • juvenile idiopathic arthritis
  • rheumatoid arthritis patients
  • combination therapy
  • systemic lupus erythematosus
  • disease activity